HMGB1 and COVID-19: Further studies are actually needed to ascertain whether plasma levels of AGEs, sRAGE, HMGB1, and S100 proteins in DM COVID-19 patients are differentially affected by conventional vs. intensive insulin therapy and are predictive of patients' outcome.